Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

20020009.LumA

— · A

f379ca37-930f-58e0-8874-e1497bae80c5

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
A
subtype
A

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.460
  • TGF_BETA_SIGNALING+0.380
  • UV_RESPONSE_DN+0.370
  • ANGIOGENESIS+0.350
  • ESTROGEN_RESPONSE_EARLY+0.330
  • NOTCH_SIGNALING+0.290
  • COAGULATION+0.260
  • TNFA_SIGNALING_VIA_NFKB+0.240
  • ANDROGEN_RESPONSE+0.230
  • PROTEIN_SECRETION+0.230

Top 10 suppressed

  • E2F_TARGETS-0.550
  • G2M_CHECKPOINT-0.510
  • MYC_TARGETS_V2-0.500
  • INTERFERON_ALPHA_RESPONSE-0.480
  • MYC_TARGETS_V1-0.480
  • INTERFERON_GAMMA_RESPONSE-0.370
  • MTORC1_SIGNALING-0.350
  • ALLOGRAFT_REJECTION-0.340
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.290
  • SPERMATOGENESIS-0.200

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
120020070.LumA
breast-umap@18
—A0.918
2TCGA-D8-A146-01A-31R-A115-07
breast-umap@18
—A0.897
3TCGA-EW-A1IX-01A-12R-A144-07
breast-umap@18
—A0.891
4TCGA-E9-A1NH-01A-11R-A14D-07
breast-umap@18
—A0.886
5SRR8613790
breast-umap@18
—A0.881
620030071.Her2HRpos
breast-umap@18
—A0.881
7TCGA-HD-7831-01A-11R-2132-07
head-neck@1
——0.877
820050073.LumB
breast-umap@18
—B0.869
9TCGA-AN-A0XL-01A-11R-A10J-07
breast-umap@18
—A0.859
10TCGA-AR-A24W-01A-11R-A169-07
breast-umap@18
—A0.856

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 22 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.460Inavolisib— uncovered
TGF_BETA_SIGNALING0.380Inavolisib— uncovered
UV_RESPONSE_DN0.370Inavolisib— uncovered
ANGIOGENESIS0.350Remibrutinib— uncovered
ESTROGEN_RESPONSE_EARLY0.330Inavolisib— uncovered
NOTCH_SIGNALING0.290Inavolisib— uncovered
COAGULATION0.260Binimetinib— uncovered
TNFA_SIGNALING_VIA_NFKB0.240Inavolisib— uncovered
ANDROGEN_RESPONSE0.230Inavolisib— uncovered
PROTEIN_SECRETION0.230Remibrutinib— uncovered
MYOGENESIS0.200Inavolisib— uncovered
APOPTOSIS0.190Idelalisib— uncovered
HEDGEHOG_SIGNALING0.190Inavolisib— uncovered
APICAL_JUNCTION0.180Inavolisib— uncovered
KRAS_SIGNALING_UP0.170Inavolisib— uncovered
HYPOXIA0.130Idelalisib— uncovered
P53_PATHWAY0.110Idelalisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.110Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.090Idelalisib— uncovered
FATTY_ACID_METABOLISM0.070Inavolisib— uncovered